Gabelli & Co. Initiates Coverage on CPEX Pharmaceuticals (CPEX) with a Buy
CPEX Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Gabelli & Co. initiates coverage on CPEX Pharmaceuticals, Inc (Nasdaq: CPEX) with a Buy. Price target $17.
Gabelli analyst says, "The market appears to be valuing CPEX Pharmaceuticals based on the company's nasal insulin product, Nasulin; we feel that this does not adequately reflect the value of the company's Testim royalty stream - we expect that the Paragraph IV generic drug filing against Testim and the increased R&D expenses to support Nasulin will continue to be a drag on the stock, however several catalysts could emerge over the next 12-18 months: settlement with Upsher-Smith, early termination/partnering of Nauslin, success of MannKind's Technosphere Insulin, new partnership opportunities, and the possibility of acquisition."
CPEX Pharmaceuticals, Inc. is a specialty pharmaceutical company.
Gabelli analyst says, "The market appears to be valuing CPEX Pharmaceuticals based on the company's nasal insulin product, Nasulin; we feel that this does not adequately reflect the value of the company's Testim royalty stream - we expect that the Paragraph IV generic drug filing against Testim and the increased R&D expenses to support Nasulin will continue to be a drag on the stock, however several catalysts could emerge over the next 12-18 months: settlement with Upsher-Smith, early termination/partnering of Nauslin, success of MannKind's Technosphere Insulin, new partnership opportunities, and the possibility of acquisition."
CPEX Pharmaceuticals, Inc. is a specialty pharmaceutical company.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Macquarie Starts Scripps Networks Interactive (SNI) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Gabelli & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
